Aurobindo Pharma USA, Inc., a wholly owned subsidiary of Aurobindo Pharma, has received approval from the U.S. Federal Trade Commission (FTC) to proceed with its acquisition of Lannett Company LLC. 

The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to close before the end of June 2026.

The acquisition marks a significant step in Aurobindo USA’s strategy to strengthen its presence in the U.S. generic pharmaceutical market. Pennsylvania-based Lannett specializes in the development and commercialization of a diversified portfolio of complex, non-opioid controlled substances. 

Through the transaction, Aurobindo USA will expand its product portfolio in this segment while gaining a U.S.-based manufacturing facility.

A key asset in the deal is Lannett’s manufacturing site in Seymour, Indiana, which has the capacity to scale production to approximately 4 billion doses annually. 

The facility is expected to enhance Aurobindo USA’s domestic manufacturing capabilities and support ongoing efforts to strengthen pharmaceutical supply chain resilience and increase U.S.-based drug production.

The company said the acquisition is expected to be immediately accretive to Aurobindo Group’s earnings per share. Beyond the near-term financial benefits, the transaction is anticipated to generate cost efficiencies, SG&A synergies, and operational integration advantages. It will also add a differentiated pipeline of complex generics and controlled substances, supporting long-term growth.

Swami S. Iyer, Chief Executive Officer of Aurobindo Pharma USA, said, “This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our U.S.-based manufacturing capabilities, and enhances our position in complex, non-opioid controlled substances.”

“We are confident it will deliver immediate earnings accretion while creating long-term value for our shareholders through operational synergies and pipeline expansion,” added Iyer.

Tim Crew, Chief Executive Officer of Lannett Company, added, “We are delighted to be joining forces with Aurobindo. As one of the nation’s oldest generic pharmaceutical companies, Lannett has a proud history of helping patients access affordable medicines. Aurobindo’s market reach and resources will help make our portfolio of medicines even more affordable and accessible for patients everywhere."

“Our board and owners extend their sincere appreciation to the outstanding teams at both companies whose professionalism, commitment, and hard work have successfully brought us to this important moment,” added Crew.